Gilead Q2 revenue $6.6B (+5%); EPS down to $0.83 on $525M legal charge; guidance raised ex-Veklury

GILEAD SCIENCES, INC.

2023-Q2 EPS reported $1.63 revenue$12,951,000,000

Total product sales ex-Veklury up 11% to $6.3B; HIV sales up 9% to $4.6B, Biktarvy up 17% to $3.0B.
Oncology sales up 38% to $728M; Trodelvy up 63% to $260M, Cell Therapy up 27% to $469M.
GAAP diluted EPS $0.83 vs $0.91 YoY; non-GAAP EPS $1.34 vs $1.58; impact of $0.32 from $525M HIV antitrust litigation accrual.
Full-year 2023 guidance: total product sales raised to $26.3-26.7B (prev $26.0-26.5B); ex-Veklury raised to $24.6-25.0B; Veklury lowered to ~$1.7B (prev ~$2.0B).
GAAP EPS guidance lowered to $4.50-4.85 (prev $4.75-5.15); non-GAAP EPS lowered to $6.45-6.80 (prev $6.60-7.00).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GILEAD SCIENCES, INC. reported the quarter ended June 30, 2023 results: revenue $6.6 billion, EPS $0.83 per share (GAAP diluted).

Period: the quarter ended June 30, 2023
Revenue: $6.6 billion
EPS: $0.83 per share (GAAP diluted)
Result: reported results

Exact text from the filing

Total second quarter 2023 revenue increased 5% to $6.6 billion compared to the same period in 2022

View on SEC.gov

Browse all earnings releases →

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000882095-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.